Compare VTGN & EPOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTGN | EPOW |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 24.2M |
| IPO Year | 2014 | 2019 |
| Metric | VTGN | EPOW |
|---|---|---|
| Price | $0.26 | $0.55 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 119.4K |
| Earning Date | 06-16-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.53 |
| 52 Week High | $5.14 | $1.86 |
| Indicator | VTGN | EPOW |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 39.96 |
| Support Level | $0.20 | N/A |
| Resistance Level | $0.66 | $0.73 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 10.27 | 2.60 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).